PDSB PDS Biotechnology Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472091 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.4%
ROA-121.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.62x
Interest coverage-3.52x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-49.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $19.03M | $22.57M |
| SG&A expense | $12.52M | $13.76M |
| Operating income | -$31.54M | -$36.32M |
| Interest expense | $5.34M | $4.67M |
| Pretax income | -$35.67M | -$38.48M |
| Income tax | -$1.17M | -$869,169 |
| Net income | -$34.50M | -$37.61M |
| EBITDA | -$31.52M | -$36.30M |
| EPS (basic) | -0.74 | -1.03 |
| EPS (diluted) | -0.74 | -1.03 |
| Weighted avg. shares (diluted) | 46.38M | 36.45M |
| Balance sheet | ||
| Cash & equivalents | $26.71M | $41.69M |
| Current assets | $28.25M | $45.05M |
| PP&E, net | $120,184 | $142,020 |
| Total assets | $30.49M | $45.36M |
| Current liabilities | $9.48M | $17.09M |
| Total liabilities | $21.24M | $26.35M |
| Shareholders' equity | $9.25M | $19.00M |
| Shares outstanding | 54.88M | 37.99M |
| Cash flow statement | ||
| Operating cash flow | -$27.75M | -$35.03M |
| Capital expenditure | $0 | $29,000 |
| Free cash flow | -$27.75M | -$35.06M |
| Investing cash flow | $0 | -$29,000 |
| Financing cash flow | $12.77M | $20.19M |
| Depreciation & amortization | $21,836 | $21,112 |
| Stock-based compensation | $4.11M | $6.85M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.